News and Trends 27 Jan 2023 Dupixent gets EU nod for children with severe atopic dermatitis …co-morbid diseases. These diseases include approved indications for Dupixent, such as atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and prurigo nodularis, as well as investigational diseases such as… January 27, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 Research looks to make drug appear like brain tumor ‘food’ …The results have been published in Pharmaceutics (Adekeye, Needham et al. 2023), in a new paper entitled, “Low-Density Lipoprotein Pathway Is a Ubiquitous Metabolic Vulnerability in High Grade Glioma Amenable… March 8, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 14 Jan 2019 Life in Bioplastic, it’s More Fantastic …There are other highly-versatile polymers but there are no known natural metabolic pathways. Metabolic and protein engineering can help. Carbios announced in 2016 that it had managed to create a… January 14, 2019 - 10 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 27 Aug 2025 Zemcelpro, the first blood cord expansion therapy to reach the EU market …and engraft effectively, while also improving what the company calls their “metabolic fitness.” According to ExCellThera, UM171 not only drives stem cell expansion but also enhances the metabolic fitness of… August 27, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2025 Vandria reports VNA-318’s first-in-human data in Alzheimer’s …cell to clean out dysfunctional organelles and renew its energy-producing network. Research has shown that metabolic cues can directly regulate autophagy and mitophagy pathways, with energetic stress often serving as… December 2, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 6 Jun 2022 Releasing the microbiome’s potential to restore European soils …groups that are already in the soil. To do this, we have found that assessing metabolic diversity and metabolic rate is far more important than getting the list of microbial… June 6, 2022 - 9 minutesmins - By Carlos de Rojas Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Poxel publishes ALD studies Two preclinical articles have been published in different journals for treatments being developed by French biopharmaceutical company, Poxel. Poxel develops treatments for chronic, serious diseases with metabolic pathophysiology including non-alcoholic… July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2025 Top biotech deals in May 2025 …activate G proteins that trigger certain signaling pathways. Specifically, the small molecules will be directed towards the GLP-1, GIP, and glucagon receptors, which are linked to metabolic diseases and obesity…. June 2, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2017 French Biotech’s Type 1 Diabetes Candidate Ready to Battle it Out with Big Pharma …kill other immune cells that are attacking the pancreas. It appears that Adocia is attempting to take this area of the metabolic diseases field by storm, and so far it… December 7, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 25 Sep 2024 How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market …metabolic diseases In 1982, an endocrinologist from UCSF named John Baxter founded a company. This company, California Biotechnology (or CalBio for short), was set on developing a drug to treat… September 25, 2024 - 9 minutesmins - By Jennifer Tsang Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jul 2019 The Top 10 Biotechs You’ll Find in Lyon …property. Poxel Poxel develops treatments for metabolic diseases. The company’s lead drug candidate is an oral treatment for type 2 diabetes that acts simultaneously in the pancreas, liver and muscles… July 10, 2019 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Apr 2019 French First-in-Class Diabetes Drug Nails Phase III Trial …to the mitochondria, the structures that generate energy within cells, plays a key role in the progression of metabolic diseases. With this unique method of action, imeglimin has the potential… April 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email